OptiBiotix Health plc (LON:OPTI), a life sciences business developing compounds to tackle obesity, cardiovascular disease and diabetes, announces it has been invited to present its research and commercial developments at the 18th edition of Expoquimia-World Chemical Summit (‘Expoquimia’) in Barcelona, Spain, on 5 October 2017.
Expoquimia is a multidisciplinary event held triennially in which the industry, professional associations, governments and academia come together to discuss future opportunities and challenges in industrial chemistry and biotechnology. In its previous edition, it had over 600 exhibitors and 38,000 visitors, making it one of the largest industrial chemistry events in Europe.
The Company will present the presentation titled: ‘New approaches: microbiome modulation as therapeutic intervention’, which will provide an overview of the wide array of existing strategies to modulate the microbiome to support human health, with a special focus on OptiBiotix’s technology platforms for the development of novel prebiotics and probiotics.
Stephen O’Hara, CEO of OptiBiotix Health plc, commented: “This invitation shows that OptiBiotix is being increasingly regarded as a key player in microbiome science and industrial biotechnology. The interest in our OptiScreen® and OptiBiotic® platforms suggests that the industry believes we are developing commercially-attractive products that will need to be manufactured at an industrial scale in the near future. We are very excited to take part and feel very honoured and thankful to the organisers for considering us.”
